[go: up one dir, main page]

WO2008033990A2 - Compositions et procédés de modulation de la voie de transduction du signal notch - Google Patents

Compositions et procédés de modulation de la voie de transduction du signal notch Download PDF

Info

Publication number
WO2008033990A2
WO2008033990A2 PCT/US2007/078375 US2007078375W WO2008033990A2 WO 2008033990 A2 WO2008033990 A2 WO 2008033990A2 US 2007078375 W US2007078375 W US 2007078375W WO 2008033990 A2 WO2008033990 A2 WO 2008033990A2
Authority
WO
WIPO (PCT)
Prior art keywords
nack
polypeptide
notch
nucleic acid
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2007/078375
Other languages
English (en)
Other versions
WO2008033990A3 (fr
Inventor
Anthony J. Capobianco
Maria-Clotilde Alves Guerra
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wistar Institute of Anatomy and Biology
Original Assignee
Wistar Institute of Anatomy and Biology
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wistar Institute of Anatomy and Biology filed Critical Wistar Institute of Anatomy and Biology
Publication of WO2008033990A2 publication Critical patent/WO2008033990A2/fr
Publication of WO2008033990A3 publication Critical patent/WO2008033990A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals

Definitions

  • Notch signal transduction pathway is an evolutionarily conserved mechanism to mediate fundamental decisions in stem cell maintenance and differentiation in many tissue types. For example, Notchl signaling is critically important for cell fate decisions during hematopoiesis .
  • Notch signaling plays a direct role during many of the bifurcation points, including the transition from common lymphoid progenitor cell to mature T cell .
  • the mammalian NOTCH gene family consists of 4 closely related members ⁇ N0TCH1-N0TCH4) . Substantial evidence now indicates that NOTCHl 1 N0TCH2 and N0TCH3 play direct roles in leukemogenesis .
  • the Notchl locus was found to be involved in the chromosomal translocation t(7;9) (q34,-q34.3) in SUP-Tl cells derived from human T-cell Acute Lymphocytic Leukemia (T-ALL) .
  • T-ALL human T-cell Acute Lymphocytic Leukemia
  • the sequence encoding most of the extracellular domain is replaced with sequence derived from the T-cell receptor ⁇ locus.
  • N 1C intracellular Notch
  • this translocation is relatively rare, the intracellular portion of Notch (N 1C ) is constitutively active in nearly half of all T-ALLs, by alternative mutations m the Notch gene.
  • Notch signaling is initiated after direct interaction between Notch and a Delta/Serrate/lag-2 (DSL) ligand presented on an adjacent cell. This interaction results m proteolytic processing that releases N 1C from the plasma membrane. N 1C then translocates to the nucleus where it interacts with the DNA binding protein CSL and the co- activator protein Mastermmd-likel (Mamll) to activate transcription of target genes. Evidence suggests other proteins might be associated with Notch, CSL, and Mamll m this activator complex. The mechanism by which this Notch complex regulates transcription is being actively investigated. Even though the exact mechanism by which N 1C drives tumo ⁇ genesis is not entirely understood, it is clear that N 1C must accumulate m the nucleus and incorporate into the activator complex.
  • DSL Delta/Serrate/lag-2
  • the present invention is an isolated pl80 NACK polypeptide or fragment thereof.
  • An isolated nucleic acid molecule encoding the pl80 NACK polypeptide, or which hybridizes to the same is also provided, as is a vector containing the nucleic acid molecule and host cell harboring said vector. While some embodiments embrace an antibody that selectively binds the pl80 NACK polypeptide or fragment, other embodiments embrace a fusion protein composed of a heterologous tag fused to the pl80 NACK polypeptide or pl80 NACK fragment.
  • the present invention is also a screening method for identifying an agent that modulates Notch-mediated signal transduction.
  • the method involves contacting a pl80 NACK polypeptide or cell expressing said polypeptide with a test agent and determining whether said agent modulates the expression or activity of the pl80 NACK polypeptide thereby identifying an agent that modulates Notch-mediated signal transduction.
  • a method for modulating Notch-mediated signal transduction using an agent identified by said screening method is also provided.
  • Figure 1 shows an amino acid sequence alignment of mouse pl80 NACK and homologs thereof from human (SEQ ID N0:3), rhesus monkey (SEQ ID NO: 4), canine (SEQ ID NO: 5), bovine
  • a serine/threonine protein kinase catalytic domain is indicated (###, Figure ID) as are conserved sequence motifs (SEQ ID NO:9-19).
  • Figure 2 shows that pl80 N ⁇ CK is a coactivator of Notch- dependent transcription as determined using an H1299 8xCSL reporter luciferase.
  • This protein is a previously uncharacterized protein known as FLJ00269 or D8Ertd82e (SEQ ID NO : 7 ; GENBANK Accession No. NP_766499) . Because this protein binds to Notch and modulates Notch- mediated-CSL target gene activity, the protein was designated pl80 NACK ; pl80 denoting the size of the protein and NACK for Notch Activation Complex Kinase.
  • the pl80 NACK proteins and nucleic acids disclosed herein find application in the development of novel anti -neoplastic therapeutics with specificity to tumors harboring mutations in the Notch pathway.
  • tumors exhibiting aberrant Notch activity include, but are not limited to, lymphoma, melanoma, and cancers of the breast, lung, colon, central nervous system and pancreas. Furthermore, manipulation of Notch activity through pl80 NACK protein is useful in regulating stem cell growth and differentiation.
  • the present invention relates to an isolated pl80 NACK nucleic acid and polypeptide encoded thereby.
  • the invention further relates to fragments and orthologs of the pl80 NACK polypeptide, as well as anti- pl80 NACK antibodies, iRNA targeting the endogenous pl80 NACK locus, screening assays for identifying agents which modulate pl80 NACK activity, and methods for treating diseases and conditions associated with aberrant Notch activity.
  • isolated means a polypeptide, peptide, nucleic acid molecule, or antibody that is in a form that is relatively free from contaminating lipids, polypeptides, nucleic acids or other cellular material normally associated with the polypeptide, peptide or nucleic acid molecule in a cell.
  • the term isolated means that the polypeptide, peptide, nucleic acid molecule, or antibody is 85%, 90%, 96%, 97%, 98%, 99%, or 100% pure.
  • pl80 NACK encompasses a polypeptide having the sequence of the murine pl80 NACK polypeptide (SEQ ID NO: 2) and is intended to include orthologs of murine pl80 NACK i . e , pl 80 NACK polypeptides found in other species, which are derived from a common ancestor and have substantial amino acid sequence identity with murine pl80 NACK (SEQ ID NO : 2 ) .
  • Exemplary mammalian pl80 NACK orthologs are shown in Figure 1 and include polypeptides isolated from rat, rhesus monkey, bovine, canine and human. While these polypeptides have been annotated as hypothetical proteins in the prior art, the substantial amino acid sequence identity of these proteins with murine pl80 NACK indicates that they are indeed orthologs of murine pl80 NACK [see Table 1) .
  • pl80 NACK describes polypeptides generally having an amino acid sequence with greater than about 60% identity, desirably greater than about 65% identity, more desirably greater than about 75% identity, and can be a polypeptide having greater than about 80%, 90%, 95%, 97%, or 99% amino acid sequence identity with murine pl80 N ⁇ CK (SEQ ID NO: 2) .
  • polypeptides having such substantial amino acid sequence identity with murine pl80 NACK include those set forth in SEQ ID N0:3, SEQ ID NO : 4 , SEQ ID NO : 5 , SEQ ID NO : 6 , and SEQ ID NO: 8.
  • the term "substantial amino acid sequence identity" when used in reference to a pl80 NACK amino acid sequence is intended to mean the pl80 NACK sequence shown in Figure 1, or a similar, non-identical sequence that is considered by those skilled in the art to be a functionally equivalent amino acid sequence.
  • an amino acid sequence that has substantial amino acid sequence identity with pl80 N ⁇ CK can have one or more modifications such as amino acid additions, deletions or substitutions relative to the amino acid sequence of pl80 NACK
  • sequences for substantial amino acid sequence identity can be performed between two sequences of any length and usually is performed with amino acid sequences of between 6 and 1400 amino acid residues. Such comparisons for substantial amino acid sequence identity are performed using methodology routine in the art, e.g., using algorithms such as CLUSTALW or DIALIGN, and are useful for identifying regions which can be modified without affecting activity.
  • amino acid sequence comparisons between murine pl80 NACK and its orthologs identified conserved amino acid sequence motifs (SEQ ID NO: 9-19) which may be essential to the function of pl80 NACK .
  • conserved amino acid sequence motifs SEQ ID NO: 9-19
  • the serine/threonine protein kinase catalytic domain depicted in Figure ID is essential to the activity of pl80 NACK . Therefore, it is contemplated that one or more modifications in the non- conserved regions of pl80 NACK can be made, wherein the resulting mutant retains at least one biological activity of pl80 NACK .
  • pl80 NACK polypeptide polypeptide sequence set forth in SEQ ID NO : 2.
  • modifications can be deliberate, as through site-directed mutagenesis, or can be accidental such as through mutation in hosts harboring a pl80 NACK encoding nucleic acid. All such modified polypeptides are included in the definition of a pl80 NACK polypeptide as long as at least one biological function of pl80 NACK is retained. Further, various molecules can be attached to a pl80 NACK polypeptide including, for example, other polypeptides, carbohydrates, lipids, or chemical moieties. Such modifications are included within the definition of a pl80 NACK polypeptide.
  • the present invention also provides fragments of a pl80 NACK polypeptide.
  • the term fragment means a polypeptide fragment having substantially the same amino acid sequence as a portion of a pl80 N ⁇ CK polypeptide.
  • a fragment of the instant invention includes both biologically active fragments of pl80 NACK , e.g., fragments that bind to Notch and modulate Notch-mediated transcription, as well as immunogenic fragments of pl80 NACK for producing anti-pl80 NACK antibodies.
  • a fragment of pl80 NACK is defined as a peptide of 5 to 250 amino acid residues in length.
  • a fragment of pl80 NACK is defined as a peptide of 6 to 100 amino acid residues, 7 to 50 amino acid residues, or 10 to 25 amino acid residues in length. Particular embodiments of the present invention explicitly exclude from the definition of a fragment a polypeptide set forth in SEQ ID NO: 7.
  • a pl80 NACK polypeptide, or fragment thereof, can be assayed for activity using one of the assays described herein or using another assay for measuring cell differentiation or cell survival known in the art.
  • a soluble pl80 NACK polypeptide or fragment thereof can be assayed by introducing an expression vector containing a nucleic acid molecule encoding the soluble pl80 NACK polypeptide or fragment into a cell and subsequently assaying for cell survival .
  • a pool of modified pl80 NACK polypeptide or pl80 NACK fragments can be assayed for activity en masse. For example, to identify an active fragment of pl80 NACK , pools of synthetic pl80 NACK fragments or pools of cell supernatants can be assayed for the ability to bind Notch; subsequently, pools of fragments or supernatants with activity can be subdivided, and the assay repeated in order to isolate the active modified pl80 N ⁇ CK polypeptide or fragment from the active pool .
  • An isolated pl80 NACK polypeptide, or fragment thereof can be obtained by a variety of methods known within the art, including biochemical, recombinant and chemical synthesis methods.
  • Biochemical methods for isolating a pl80 NACK polypeptide, or fragment thereof include preparative gel electrophoresis, gel filtration, affinity chromatography, ion exchange and reversed phase chromatography, chromatofocusing, isoelectric focusing and sucrose or glycerol density gradients (see, for example, Chapter 38 of Guide to Protein Purification, Vol. 182, Academic Press, Inc., San
  • pl80 NACK was isolated by immunoprecipitation.
  • Preparative gel electrophoresis can be useful in preparing an isolated pl80 NACK polypeptide or fragment of the invention.
  • a pl80 NACK polypeptide, or fragment thereof can be isolated by preparative polyacrylamide gel electrophoresis and elution of the polypeptide or fragment by diffusion or electroelution (see, for example, Chapter 33 of Irishr, supra, 1990) .
  • Continuous elution gel electrophoresis using a system such as the Model 491 Prep Cell (BIORAD, Hercules, CA) can be used to purify a pl80 NACK polypeptide, or fragment thereof.
  • continuous elution gel electrophoresis can be combined with further purification steps such as liquid phase preparative isoelectric focusing using, for example, the ROTOFOR system (BIO-RAD) .
  • Affinity chromatography is particularly useful in preparing an isolated pl80 NACK polypeptide or fragment of the invention.
  • a polypeptide that interacts with a pl80 NACK polypeptide for example, a Notch polypeptide, can be useful as an affinity matrix for isolating a pl80 NACK polypeptide or active fragment of the invention.
  • polypeptide fragments such as fragments of Notch also can be useful affinity matrices for isolating a pl80 NACK polypeptide or fragment of the invention.
  • Immunoaffinity chromatography can be particularly useful in isolating a pl80 NACK polypeptide or active fragment thereof.
  • immunoprecipitation or column chromatography with an antibody that selectively binds pl80 NACK can be used to isolate a pl80 NACK polypeptide or fragment thereof.
  • An anti-pl80 NACK monoclonal or polyclonal antibody that selectively binds pl80 NACK can be prepared using an immunogen such as the sequence shown as SEQ ID NO : 2 , or a synthetic peptide fragment thereof, as described herein.
  • a particularly useful immunogen can be a synthetic peptide fragment of SEQ ID NO : 2 having a sequence that is relatively unique to pl80 NACK .
  • T-cell lymphomas expressing a FLAG- tagged Nic were generated in mice by retroviral transduction mouse bone marrow cells. Following formation of lymphoma in mice (approximately 12 weeks) the lymphomatous tissue was harvested and prepared for purification of Notch complexes.
  • Nic-associated proteins were purified by anti-FLAG affinity purification. To determine the identity of the Nic-associated proteins, the FLAG affinity eluate was separated on a polyacrylamide gel, bands were stained with colloidal blue, and individual polypeptides were excised from the gel and subjected to mass spectrometric analysis using LC MS/MS.
  • a pl80 NACK polypeptide or pl80 NACK fragment of the invention can also be produced by chemical synthesis, for example, by the solid phase peptide synthesis method of Merrifield, et al . (1964) J. Am. Chem. Soc. 85:2149.
  • Standard solution methods well-known in the art also can be used to synthesize a polypeptide or fragment useful in the invention (see, e.g., Bodanszky (1984) Principles of Peptide Synthesis, Springer-Verlag, Berlin and Bodanszky (1993) Peptide Chemistry, Springer-Verlag, Berlin) .
  • a newly synthesized polypeptide or fragment can be purified, for example, by high performance liquid chromatography (HPLC) and can be characterized using mass spectrometry or amino acid sequence analysis.
  • HPLC high performance liquid chromatography
  • Recombinant methods for producing a polypeptide through expression of a nucleic acid sequence in a suitable host cell are well-known and routinely practiced in the art. Such methods are described, for example, in Sambrook et al . , Molecular Cloning: A Laboratory Manual, 2nd Ed, VoIs 1 to 3, Cold Spring Harbor Laboratory Press, New York (1989) . Suitable expression vectors for use in eukaryotic and prokaryotic host cells can be readily obtained from commercial sources such as CLONTECH and STRATAGENE . By way of illustration, production of recombinant pl80 NACK polypeptide is provided in Example 2.
  • a recombinant pl80 NACK polypeptide or fragment of the invention can be expressed as a fusion protein with a heterologous "tag" for convenient isolation from bacterial or mammalian host proteins.
  • Histidine-tagged recombinant pl80 NACK can be isolated by nickel-chelate chromatography.
  • a glutathione-S-transferase tag or an antigenic tag such as "FLAG, " "AU” or a myc epitope tag also can be included in a recombinant pl80 NACK polypeptide or fragment of the invention (Sambrook, et al . (1989) supra) .
  • a pl80 NACK nucleic acid molecule of the present invention includes the murine pl80 NACK cDNA set forth in SEQ ID NO : 1 , a nucleic acid molecule encoding a murine pl80 NACK polypeptide ⁇ e.g., having the sequence of SEQ ID N0:2) or a nucleic acid molecule encoding an ortholog of murine pl80 NACK polypeptide ⁇ e.g., having the sequence of SEQ ID NO : 3 , SEQ ID N0:4, SEQ ID NO : 5 , SEQ ID NO : 6 , or SEQ ID NO: 8) .
  • the invention provides pl80 NACK nucleic acid molecules of at least 8 nucleotides in length (i.e., a hybridizable portion), as well as pl80 NACK nucleic acid molecules of 25, 50, 100, 150, or 200 (continuous) nucleotides in length, or a full-length pl80 NACK coding sequence.
  • the invention also relates to nucleic acid molecules hybridizable to or complementary to the foregoing sequences or their complements.
  • nucleic acids are provided which encompass a sequence complementary to at least 10, 25, 50, 100, or 200 nucleotides or the entire coding region of a pl80 NACK .
  • a nucleic acid which is hybridizable to a mammalian pl80 NACK nucleic acid molecule ⁇ e.g., having sequence SEQ ID N0:l, or a 10, 25, 50, 100, or 200 nucleotide portion thereof), or to a nucleic acid encoding a pl80 NACK ortholog, under conditions of low stringency is provided.
  • procedures using such conditions of low stringency are as follows (see also Shilo and Weinberg
  • filters containing DNA are pretreated for 6 hours at 4O 0 C in a solution containing 35% formamide, 5X SSC, 50 mM Tris-HCl
  • Hybridizations are carried out in the same solution with the following modifications: 0.02% PVP, 0.02% FICOLL, 0.2% BSA, 100 ⁇ g/ml salmon sperm DNA, 10% (wt/vol) dextran sulfate, and 5-20 x 10 G cpm 32 P-labeled probe is used.
  • Filters are incubated in hybridization mixture for 18-20 hours at 40 0 C, and then washed for 1.5 hours at 55°C in a solution containing 2X SSC, 25 mM Tris-HCl (pH 7.4), 5 mM EDTA, and 0.1% SDS. The wash solution is replaced with fresh solution and incubated an additional 1.5 hours at 60 0 C. Filters are blotted dry and exposed for autoradiography. If necessary, filters are washed for a third time at 65-68 0 C and re-exposed to film. Other conditions of low stringency which may be used are well-known in the art (e.g., as employed for cross-species hybridizations) .
  • a nucleic acid which is hybridizable to a mammalian pl80 NACK nucleic acid molecule under conditions of high stringency is provided.
  • procedures using such conditions of high stringency are as follows: prehybridization of filters containing DNA is carried out for 8 hours to overnight at 65 0 C in buffer composed of 6X SSC, 50 ⁇ iM Tris-HCl (pH 7.5), 1 mM EDTA, 0.02% PVP, 0.02% FICOLL, 0.02% BSA, and 500 ⁇ g/ml denatured salmon sperm DNA.
  • Filters are hybridized for 48 hours at 65 0 C in prehybridization mixture containing 100 ⁇ g/ml denatured salmon sperm DNA and 5-20 x 10 s cpm of 32 P-labeled probe. Washing of filters is done at 37°C for 1 hour in a solution containing 2X SSC, 0.01% PVP, 0.01% FICOLL, and 0.01% BSA. This is followed by a wash in 0. IX SSC at 5O 0 C for 45 minutes before autoradiography. Other conditions of high stringency which can be used are well known in the art.
  • nucleic acids encoding fragments of pl80 NACK and modified pl80 NACK polypeptides, antisense, and pl80 N ⁇ CK iRNA nucleic acids are additionally provided.
  • a nucleic acid molecule encoding a fragment or portion of a pl80 NACK polypeptide shall be construed as referring to a nucleic acid encoding only the recited fragment or portion of the pl80 NACK polypeptide and not the other contiguous portions of the pl80 NACK polypeptide.
  • Nucleic acid molecules such as antisense and iRNA which hybridize or interfere with the expression pl80 NACK polypeptide are also embraced by the present invention.
  • Synthetic siRNA, or pairs of short complimentary RNA molecules, or a single inverted small hairpin RNA (shRNA) are useful for RNAi -mediated inhibition of expression.
  • the identification of suitable iRNA target regions in a nucleic acid of interest is routinely practiced in the art using commercially available algorithms (see, e.g., Khvorova, et al . (2003) Cell 115 (2) :209-16; Schwarz, et al (2003) Cell 115 (2) : 199-208 ; Reynolds, et al . (2004) Nat.
  • kits for production of dsRNA for use in RNAi are available commercially, e.g., from New England Biolabs, Inc. and AMBION Inc. (Austin, TX). Methods of transfection of dsRNA or plasmids engineered to make dsRNA are routine in the art.
  • siRNA molecules When employing an siRNA molecule, said molecules are generally 19-30 nucleotides in length and have a GC content of 40-60%. Examples of siRNA molecules useful in decreasing the expression of a pl80 NACK polypeptide are provided in Table 2.
  • Cloning of a pl80 NACK nucleic acid molecule of the present invention can be carried out using methods routinely practiced in the art, including but not limited to expression cloning, nucleic acid hybridization and PCR amplification.
  • an expression library is constructed by isolating mRNA (e.g., human), producing cDNA and ligating the cDNA into an expression vector (e.g., a bacteriophage derivative) such that it is capable of being expressed by the host cell into which it is then introduced.
  • an expression vector e.g., a bacteriophage derivative
  • Various screening assays can then be used to select for the expressed pl80 NACK product.
  • anti-pl80 NACK antibodies can be used for selection.
  • PCR is used to amplify a pl80 NACK nucleic acid molecule.
  • Oligonucleotide primers representing known pl80 NACK sequences (desirably mammalian sequences) are used as primers in PCR.
  • the oligonucleotide primers represent at least a part of the nucleic acid molecule encoding a pl80 NACK conserved motif of substantial amino acid sequence identity with murine pl80 NACK .
  • Synthetic oligonucleotides can be utilized as primers to PCR amplify a pl80 NACK nucleic acid molecule using an RNA or DNA, e.g., a cDNA or genomic library, from any source as template.
  • PCR can be carried out, e.g., by use of a commercial thermal cycler and Taq polymerase.
  • That segment After successful amplification of a segment of a pl80 NACK ortholog, that segment can be cloned and sequenced, and utilized as a probe to isolate a complete cDNA or genomic clone. This, in turn, permits the determination of the gene's complete nucleic acid sequence, the analysis of its expression, and the production of its protein product for functional analysis. In this fashion, additional nucleic acid molecules encoding pl80 NACK proteins are identified.
  • any cell potentially can serve as the nucleic acid source for the molecular cloning of a pl80 NACK nucleic acid molecule of the present invention.
  • the nucleic acid molecule encoding pl80 NACK can be isolated from mammalian, human, porcine, bovine, feline, avian, equine, canine, and rat, as well as additional primate sources, etc.
  • the DNA from these source can be obtained by standard procedures known in the art for cloning DNA ⁇ e.g., a DNA library), by chemical synthesis, by cDNA cloning, or by the cloning of genomic DNA, or fragments thereof, purified from the desired cell. (See, for example, Sambrook et al . (1989) Molecular Cloning, A Laboratory Manual, 2d Ed., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, N. Y.; Glover
  • Clones derived from genomic DNA can contain regulatory and intron DNA regions in addition to coding regions. Whatever the source, the nucleic acid molecule is generally cloned into a suitable vector for propagation of the nucleic acid molecule.
  • DNA fragments are generated, some of which will encode the desired gene.
  • the DNA can be cleaved at specific sites using various restriction enzymes. Alternatively, one can use DNAse in the presence of manganese to fragment the DNA, or the DNA can be physically sheared, as for example, by sonication.
  • the linear DNA fragments can then be separated according to size by standard techniques, including but not limited to, agarose and polyacrylamide gel electrophoresis and column chromatography. Once the DNA fragments are generated, identification of the specific DNA fragment containing the desired gene can be accomplished in a number of ways.
  • the generated DNA fragments can be screened by nucleic acid hybridization to the labeled probe (Benton and Davis (1977) Science 196:180; Grunstein and Hogness (1975) Proc. Natl. Acad. Sci . USA 72:3961). Those DNA fragments with substantial homology to the probe will hybridize. It is also possible to identify the appropriate fragment by restriction enzyme digestion (s) and comparison of fragment sizes with those expected according to a known restriction map if such is available. Further selection can be carried out on the basis of the properties of the gene.
  • the presence of the gene can be detected by assays based on the physical, chemical, or immunological properties of its expressed product.
  • cDNA clones, or DNA clones which hybrid-select the proper mRNAs can be selected which produce a protein that, e.g., has similar or identical electrophoretic migration, isolectric focusing behavior, proteolytic digestion maps, binding activity, in vitro aggregation activity or antigenic properties as known for pl80 NACK .
  • the pl80 NACK polypeptide can also be identified by binding of labeled antibody to the putatively pl80 NACK synthesizing clones, in an ELISA-type procedure .
  • a pl80 NACK nucleic acid molecule can also be identified by mRNA selection by nucleic acid hybridization followed by in vitro translation. In this procedure, fragments are used to isolate complementary mRNAs by hybridization. Such DNA fragments may represent available, purified pl80 NACK DNA of another species ⁇ e.g., human). Immunoprecipitation analysis or functional assays (e.g., binding to Notch; see infra) of the in vitro translation products of the isolated mRNAs identifies the mRNA and, therefore, the complementary DNA fragments that contain the desired sequences. In addition, specific mRNAs can be selected by adsorption of polysomes isolated from cells to immobilized antibodies specifically directed against pl80 NACK polypeptide. A radiolabelled pl80 NACK cDNA can be synthesized using the selected mRNA
  • the radiolabelled mRNA or cDNA can then be used as a probe to identify the pl80 NACK nucleic acid fragments from among other genomic DNA fragments.
  • RNA for cDNA cloning of the pl80 NACK nucleic acid molecule can be isolated from cells which express pl80 NACK .
  • a nucleic acid molecule of the present invention can also be mutated to encode for a modified pl80 NACK polypeptide or fragment, for example, by site-directed mutagenesis (see Wu (Ed.) Meth. Enzymol . Vol.
  • mutagenesis can be used to introduce a specific, desired amino acid substitution, deletion or insertion; alternatively, a nucleic acid sequence can be synthesized having random nucleotides at one or more predetermined positions to generate random amino acid substitutions. Scanning mutagenesis also can be useful in generating nucleic acid molecules encoding pl80 NACK polypeptides or fragments that are modified throughout the entire polypeptide or fragment sequence. Such modified fragments can be screened for the ability to bind Notch or modify Notch mediated transcription.
  • a pl80 NACK polypeptide of the invention is useful for preparing an antibody that selectively binds a pl80 NACK polypeptide such as murine pl80 NACK (8EQ ID NO: 2) and/or a pl QQ NACK ort hoi og ( SE Q ID NO: 3, SEQ ID NO : 4 , SEQ ID NO : 5 , SEQ ID N0:6, SEQ ID NO:8).
  • An antibody that selectively binds a pl80 NACK polypeptide can be useful, for example, in purifying a pl80 NACK polypeptide by immunoaffinity chromatography.
  • Such an antibody also can be useful in screening assays for identifying small molecule inhibitors which compete for binding of the antibody to pl80 NACK polypeptide.
  • the term antibody is used in its broadest sense to include polyclonal and monoclonal antibodies, as well as polypeptide fragments of antibodies that retain selective binding activity for a pl80 NACK polypeptide of at least about 1 x 10 5 M "1 .
  • anti-pl80 NACK antibody fragments such as Fab, F(ab') 2 and Fv fragments can retain selective binding activity for a pl80 NACK polypeptide and, thus, are included within the definition of an antibody.
  • antibody as used herein includes naturally occurring antibodies as well as non-naturally occurring antibodies and fragments that have binding activity such as chimeric antibodies or humanized antibodies.
  • non-naturally occurring antibodies can be constructed using solid phase peptide synthesis or produced recombinantly .
  • Such non-naturally occurring antibodies also can be obtained, for example, by screening combinatorial libraries composed of variable heavy chains and variable light chains as described by Borrebaeck (Ed.) (1995) Antibody Engineering (Second edition) New York: Oxford University Press .
  • An antibody selective for a polypeptide also can be selective for a related polypeptide (e.g., an ortholog) .
  • an antibody selective for murine p 180 NA c ⁇ SE Q ID N0: 2 also can be selective for human pl80 NACK (SEQ ID NO: 3) or for pl80 NACK orthologs from other species ⁇ e.g., as listed in Table 1) .
  • An anti-pl80 NACK antibody can be prepared, for example, using a pl80 NACK fusion protein or a synthetic peptide encoding a portion of pl80 NACK polypeptide such as murine
  • a purified pl80 NACK polypeptide can be prepared from natural sources or produced recombinantly as described above, or fragments of pl80 NACK polypeptide, including a peptide portion of pl80 NACK such as a synthetic peptide, can be used as an immunogen.
  • Examples of immunogenic fragments of murine and human pl80 NACK polypeptide are set forth in Table 3. TABLE 3
  • Protein cleavage prediction was carried out using FRAGPREDICT and MHC binding matrices using SYFPEITHI.
  • Non- immunogenic fragments or synthetic peptides of pl80 NACK can also be made immunogenic by coupling the hapten to a carrier molecule such as bovine serum albumin (BSA) or keyhole limpet hemocyanin (KLH) .
  • BSA bovine serum albumin
  • KLH keyhole limpet hemocyanin
  • various other carrier molecules and methods for coupling a hapten to a carrier molecule are well-known in the art and described, for example, by Harlow and Lane (1988) Antibodies : A Laboratory Manual (Cold Spring Harbor Laboratory Press) .
  • the present invention also embraces vectors and host cells containing a recombinant nucleic acid molecule having a nucleotide sequence encoding a pl80 NACK polypeptide, or fragment thereof.
  • the cell can be a prokaryotic cell or a eukaryotic cell such as an HEK293 cell, H1299 cell, COS cell or BHK cell.
  • Such vectors and cells are useful for expressing a recombinant pl80 NACK polypeptide, or fragment thereof, for purification and production of antibodies as well as for determining the crystal structure of the catalytic domain.
  • a host cell transformed with a nucleic acid molecule encoding a pl80 NACK polypeptide can also be used in in vivo screening assay for determining whether a test agent modulates Notch-mediated signal transduction.
  • Notch-mediated signal transduction relates to the direct interaction between Notch and a DSL ligand which results in proteolytic processing that releases N 1C from the plasma membrane, wherein N 1C translocates to the nucleus and interacts with the DNA binding protein CSL and the co- activator protein Mastermind- likel (Mamll) to activate transcription of target genes.
  • Notch-mediated signal transduction can be determined by reporter gene expression (e.g., a CSL-responsive promoter fused to luciferase) the presence of a test agent and absence of a test agent (i.e., control) .
  • Agents identified in accordance with this in vivo assay can include agents which directly interact with the pl80 NACK polypeptide or modulate the expression of nucleic acid molecules encoding pl80 NACK polypeptide thereby changing the amount of the protein in the cell and therefore Notch-mediated signal transduction.
  • in vitro screening assays can be carried out which are based upon kinase activity or binding between Notch, or other component of a Notch complex (e.g., Mamll or CSL), and pl80 NACK polypeptide.
  • a Notch complex e.g., Mamll or CSL
  • pl80 NACK polypeptide e.g., kinase activity or binding between Notch, or other component of a Notch complex
  • pl80 NACK polypeptide generally involve contacting Notch, or a protein of the Notch complex, with pl80 NACK polypeptide in the presence or absence of a test agent and determining whether the kinase activity of pl80 NACK polypeptide is modulated or whether the interaction between Notch, or a protein of the Notch complex, with pl80 N ⁇ CK polypeptide is disrupted ⁇ e.g., via co-immunoprecipitation assays) .
  • the in vitro and in vivo screening assays disclosed herein can be performed in any format that allows rapid preparation and processing of multiple reactions such as in, for example, multi-well plates of the 96-well variety.
  • Stock solutions of test agents as well as assay components are prepared manually and all subsequent pipetting, diluting, mixing, washing, incubating, sample readout and data collecting is done using commercially available robotic pipetting equipment, automated work stations, and analytical instruments for detecting the signal generated by the assay.
  • reagents like salts, neutral proteins, e.g., albumin, detergents, etc. which can be used to facilitate optimal protein- protein binding and/or reduce non-specific or background interactions.
  • reagents that otherwise improve the efficiency of the assay such as protease inhibitors, nuclease inhibitors, anti -microbial agents, and the like can be used.
  • the mixture of components can be added in any order that provides for the requisite binding.
  • a control can be included for comparison.
  • a control can be a test reaction which lacks the test agent or a control reaction can be test reaction which contains a known agent which has a high affinity for binding and inhibiting Notch-mediated signal transduction.
  • Test agents which can be screened in accordance with the methods of the present invention are generally derived from libraries of agents or compounds. Such libraries can contain either collections of pure agents or collections of agent mixtures. Examples of pure agents include, but are not limited to, proteins, polypeptides, peptides, antibodies, nucleic acids, iRNA, antisense oligonucleotides, carbohydrates, lipids, synthetic or semisynthetic chemicals, and purified natural products. Examples of agent mixtures include, but are not limited to, extracts of prokaryotic or eukaryotic cells and tissues, as well as fermentation broths and cell or tissue culture supernates.
  • the methods of this invention are not only used to identify those crude mixtures that possess the desired activity, but also provide the means to monitor purification of the active agent from the mixture for characterization and development as a therapeutic drug.
  • the mixture so identified can be sequentially fractionated by methods commonly known to those skilled in the art which can include, but are not limited to, precipitation, centrifugation, filtration, ultrafiltration, selective digestion, extraction, chromatography, electrophoresis or complex formation. Each resulting subfraction can be assayed for the desired activity using the original assay until a pure, biologically active agent is obtained. Additional screens such as well-established computational screens are also contemplated for use in conjunction with the screening method disclosed herein.
  • Agents identified in accordance with the assay method of the present invention will be useful in various applications including inhibiting Notch-mediated signaling as well as anti-neoplastic therapeutics with specificity to tumors harboring mutations in the Notch pathway.
  • tumors exhibiting aberrant Notch activity include, but are not limited to, lymphoma, melanoma, and cancers of the breast, lung, colon, central nervous system and pancreas.
  • manipulation of Notch activity through pl80 NACK protein is useful in regulating stem cell growth and differentiation.
  • an agent identified in accordance with the assay method of the present invention in the prevention or treatment of a disease or condition involving Notch- mediated signal transduction typically involves the steps of first identifying a patient at risk of having or having a disease or disorder involving Notch-mediated signal transduction ⁇ e.g., lymphoma, melanoma, and cancers of the breast, lung, colon, central nervous system and pancreas) . Once such an individual is identified using, for example, standard clinical practices, said individual is administered a pharmaceutical composition containing an effective amount of an agent identified in the screening methods of the invention.
  • a disease or disorder involving Notch-mediated signal transduction e.g., lymphoma, melanoma, and cancers of the breast, lung, colon, central nervous system and pancreas
  • compositions can be in the form of pharmaceutically acceptable salts and complexes and can be provided in a pharmaceutically acceptable carrier and at an appropriate dose.
  • Such pharmaceutical compositions can be prepared by methods and contain carriers which are well-known in the art. A generally recognized compendium of such methods and ingredients is Remington: The Science and Practice of Pharmacy, Alfonso R.
  • a pharmaceutically-acceptable carrier, composition or vehicle such as a liquid or solid filler, diluent, excipient, or solvent encapsulating material, is involved in carrying or transporting the subject compound from one organ, or portion of the body, to another organ, or portion of the body.
  • Each carrier must be acceptable in the sense of being compatible with the other ingredients of the formulation and not injurious to the patient.
  • Examples of materials which can serve as pharmaceutically acceptable carriers include sugars, such as lactose, glucose and sucrose; starches, such as corn starch and potato starch; cellulose, and its derivatives, such as sodium carboxymethyl cellulose, ethyl cellulose and cellulose acetate; powdered tragacanth; malt; gelatin; talc; excipients, such as cocoa butter and suppository waxes; oils, such as peanut oil, cottonseed oil, safflower oil, sesame oil, olive oil, corn oil and soybean oil; glycols, such as propylene glycol; polyols, such as glycerin, sorbitol, mannitol and polyethylene glycol; esters, such as ethyl oleate and ethyl laurate; agar; buffering agents, such as magnesium hydroxide and aluminum hydroxide; alginic acid; pyrogen- free water; isotonic saline; Ringer's
  • wetting agents such as sodium lauryl sulfate and magnesium stearate, as well as coloring agents, release agents, coating agents, sweetening, flavoring and perfuming agents, preservatives and antioxidants can also be present in the compositions.
  • compositions appropriately formulated for parenteral for example, by intravenous, intraperitoneal, subcutaneous or intramuscular injection), topical (including buccal and sublingual), oral, intranasal, intravaginal , or rectal administration can be prepared according to standard methods.
  • the selected dosage level will depend upon a variety of factors including the activity of the particular agent employed, the route of administration, the time of administration, the rate of excretion or metabolism of the particular agent being employed, the duration of the treatment, other drugs, compounds and/or materials used in combination with the particular agent employed, the age, sex, weight, condition, general health and prior medical history of the patient being treated, and like factors well known in the medical arts.
  • a physician or veterinarian having ordinary skill in the art can readily determine and prescribe the effective amount of the pharmaceutical composition required. For example, the physician or veterinarian could start doses of an agent at levels lower than that required in order to achieve the desired therapeutic effect and gradually increase the dosage until the desired effect is achieved.
  • siRNAs useful for achieving the desired therapeutic result with no systemic or local adverse events.
  • Nuclear extracts of FLAG-fusion-N lc tumors (50 mg) were incubated with 100 ⁇ l of anti-FLAG M2 affinity gel (SIGMA, St. Louis, MO) overnight at 4 0 C. Beads were washed with 3 x 5 ml BC500 buffer (20 mM Tris, pH 8; 0.5 M KCl; 10% glycerol; 1 mM EDTA; 1 mM DTT; 0.1% NP-40; 0.5 mM PMSF; and aprotinin, leupeptide, and pepstatin at 1 ⁇ g/ml each) and 2 times with 5 ml BClOO buffer (20 mM Tris, pH 8; 0.1 M KCl, 10% glycerol; 1 mM EDTA; 1 mM DTT; 0.1% NP-40; and aprotinin, leupeptide, and pepstatin at 1 ⁇ g/ml each) . Bound peptides were eluted with
  • Example 2 Cloning of Nucleic Acids Encoding pl80 NACK Using PCR, mouse and human cDNAs encoding FLJ00269 protein were amplified and cloned into commercially available expression vectors. Sequence and expression were validated. From the sequence analysis, it was determined that the full 5' region of FLJ00269 encoded an additional 195 amino acids not predicted by the genome project, likely due to sequencing errors. SEQ ID NO : 1 represents the complete coding sequence and amino acid sequence of mouse FLJ00269, designated herein as pl80 NACK .
  • pl80 NACK was purified with Notch from a complex sample, the association between these two proteins was subsequently evaluated.
  • N 1C To demonstrate an in vivo interaction between pl80 NACK and N 1C , co-immunoprecipitation experiments were performed. Expression vectors encoding pl80 NACK and Notch were co-transfected into HEK293 cells.
  • NP-40 Lysis buffer 150 mM NaCl, 50 mM HEPES, pH 7.4, 1.5 mM EDTA, 10 % glycerol, 1 % NP-40, supplemented with 0.5 mM DTT, 0.2 mM PEFABLOC, 1 ⁇ g/ml leupeptin, 1 ⁇ g/ml aprotinin (ROCHE), 50 mM NaF and 0.5 mM Vanadate
  • the immuno- complexes were washed extensively with lysis buffer, and the precipitates were boiled in Laemmli buffer and assayed by western blot analysis using an anti -Notch antibody. This analysis revealed the presence of a 100 kDa band corresponding to N 1C . As a control, neither pl80 NACK nor N ic immunoprecipitated with IgG. This analysis confirmed that N ic interacts with pl80 NACK .
  • Example 4 Luciferase Reporter Assay The observed co-immunoprecipitation between N 1C and pl80 NACK indicated that pl80 NACK was targeted specifically to CSL target genes to facilitate efficient transcriptional activation by Notch. Transcription activation by Notch is essential for its normal biological and oncogenic activities. Therefore it was determined whether pl80 NACK could modulate Notch-mediated-CSL target gene activity. To demonstrate this activity, an 8xCSL luciferase reporter that contains multiple copies of an optimal CSL-binding site was employed.
  • H1299 cells were seeded on six well plates at 100,000 cells per well one day before transfection and then transfected with various combinations of expression plasmid DNA corresponding to a final amount of 2 ⁇ g of DNA. The total amount of plasmid was maintained constant by adding appropriate amounts of empty vector without insert . The transfected cells were harvested at 48 hours post- transfection and luciferase activities were measured using a commercially available luciferase reporter assay system. Luciferase values were corrected for transcription efficiency by normalizing to ⁇ -galactosidase activity.
  • pl80 NACK acts as a specific co-activator for Notch transcription.
  • the results disclosed herein clearly indicate that pl80 NACK is a critical component of the Notch pathway and tumor cell survival.
  • pl80 NACK by virtue of functionality with Notch, is a valid therapeutic target.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

La présente invention concerne un polypeptide p180NACK qui se lie à Notch et module la transduction du signal médié par Notch. L'invention concerne des molécules d'acide nucléique codant pour le polypeptide p180NACK, des anticorps qui se lient sélectivement au polypeptide p180NACK, des molécules d'ARNi qui inhibent l'expression du polypeptide p180NACK, ainsi que des procédés permettant d'identifier des agents qui modulent l'expression ou l'activité du polypeptide p180NACK. L'invention porte également sur un procédé de modulation de la transduction du signal médié par Notch au moyen desdits agents.
PCT/US2007/078375 2006-09-15 2007-09-13 Compositions et procédés de modulation de la voie de transduction du signal notch Ceased WO2008033990A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82577306P 2006-09-15 2006-09-15
US60/825,773 2006-09-15

Publications (2)

Publication Number Publication Date
WO2008033990A2 true WO2008033990A2 (fr) 2008-03-20
WO2008033990A3 WO2008033990A3 (fr) 2008-11-06

Family

ID=39184584

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/078375 Ceased WO2008033990A2 (fr) 2006-09-15 2007-09-13 Compositions et procédés de modulation de la voie de transduction du signal notch

Country Status (1)

Country Link
WO (1) WO2008033990A2 (fr)

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
DATABASE GENBANK [Online] September 2006 CARCINI ET AL.: 'Unnamed Protein Product' Database accession no. (BAC29528) *
'Glycine-Glutamine bioactive peptide' SIGMA CHEMICAL 1993 CATALOG page 1089 *
TANAKA ET AL.: 'Pragmin, a Novel Effector of Rnd2 GTPase, Stimulates RhoA Activity' J. BIOL. CHEM. vol. 281, 2006, pages 10355 - 10364, XP002501195 *

Also Published As

Publication number Publication date
WO2008033990A3 (fr) 2008-11-06

Similar Documents

Publication Publication Date Title
JP3989528B2 (ja) Ｄｎａ配列及びエンコードされた乳房に特異的な乳癌たんぱく質
US6458939B1 (en) Compositions and methods for the diagnosis, prevention, and treatment of neoplastic cell growth and proliferation
US20080063638A1 (en) Mitotic kinesin-like protein-1, MKLP1, and uses therof priority
WO1996039516A9 (fr) Cibles pour le diagnostic et le traitement du cancer du sein
JPH08510651A (ja) Ｍｔｓ遺伝子、それにおける変異、およびｍｔｓ遺伝子配列を用いる癌の診断方法
JP3681384B2 (ja) Ｇｄｐ交換因子活性を有するペプチド，それらのペプチドをコードする核酸配列，調製法，およびに，使用
EP0999273A1 (fr) GENE HUMAIN RecQ4 CODANT HELICASE
US6955905B2 (en) PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use
EP0974652A1 (fr) Gene associe a la metastase cancereuse
WO2008033990A2 (fr) Compositions et procédés de modulation de la voie de transduction du signal notch
US7112419B2 (en) Human hepatoma associated protein and the polynucleotide encoding said polypeptide
US6586579B1 (en) PR-domain containing nucleic acids, polypeptides, antibodies and methods
WO1997031110A1 (fr) Molecule de la famille des genes de transfert f, polynucleotide codant pour cette molecule et anticorps actif contre cette molecule
EP1227106A1 (fr) Protéines proapoptotiques et de molécules d'ADN codant ces protéines
US20030049623A1 (en) PR/SET-domain containing nucleic acids, polypeptides, antibodies and methods of use
US20020120104A1 (en) Myc homology region II-associated protein and uses thereof
JPWO1999040190A1 (ja) ヒトｔｓｃ４０３遺伝子及びヒトｉｎｇ１ｌ遺伝子
US20030105001A1 (en) Pro-apoptotic proteins and DNA molecules encoding them
JP2001512007A (ja) Ｚｇｇｂｐ１、１型双極性感情障害に関与する新規ペプチド、配列及びその使用
WO2000009655A2 (fr) Genes amplifies dans des cellules cancereuses
US20050095594A1 (en) Nucleic acid sequences of hyperplasies and tumors of the thyroid
EP1357181A1 (fr) Nouveaux genes et proteines associes a la dermatite atopique
JP2004505018A (ja) Ｎｅｔ−４モジュレーターを用いて新生物疾患を処置するための組成物および方法
US20030228587A1 (en) Nucleic acid molecule encoding IWU-1
WO2002057449A1 (fr) Nouveau gene tifa

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07842407

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase in:

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 07842407

Country of ref document: EP

Kind code of ref document: A2